Low-molecular-weight heparin offers no benefit to patients with unexplained recurrent miscarriage in future pregnancy

Commentary on: Schleussner E, Kamin G, Seliger G, et al., ETHIG II group. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimislation randomisation scheme. Ann Intern Med 2015;162:601–9 . Context Recurrent miscarriage (RM) has been shown to affect between 1% and–3% of couples trying to conceive and up to 5% of those with two consecutive miscarriages are included. While there are many known risk factors for RM no underlying cause is found in nearly 50% of couples.1 The treatment of RM is usually aimed at the cause, which leaves us with very little to offer those with RM of unknown aetiology, and to date most of the treatment offered is not evidence based but revolves around anecdotal evidence and personal bias.2 Research in this area has been conflicting with Badawy et al3 showing a significant reduction...
Source: Evidence-Based Medicine - Category: Internal Medicine Authors: Tags: Journalology, Drugs: cardiovascular system, Stroke, Pregnancy, Ethics Therapeutics/Prevention Source Type: research